GC
EPZM

Guggenheim Capital’s Epizyme, Inc EPZM Stock Holding History

Guggenheim Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-51,716
Closed -$972K – 3115
2015
Q1 		$972K Buy
+51,716
New +$1.07M ﹤0.01% 2250

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Guggenheim Capital's EPZM Position: Q2 2015 in Review

Guggenheim Capital sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 51,716 shares — an estimated $972K sold.

Guggenheim Capital first reported a position in EPZM in Q1 2015 and held it in 1 quarter. The position peaked at $972K in Q1 2015. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

  • Guggenheim Capital reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
  • Guggenheim Capital sold 51,716 Epizyme, Inc shares in Q2 2015, an estimated $972K.
  • Guggenheim Capital first reported a position in Epizyme, Inc in Q1 2015 and held it in 1 quarter.
  • Guggenheim Capital's Epizyme, Inc position peaked at $972K in Q1 2015.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Guggenheim Capital's 13F filing for Q2 2015, filed 14 Aug 2015.